Among 744 914 patients with heart failure and naive to SGLT2 inhibitor therapy, 28 075 began empagliflozin (15 976 [56.9%]) or dapagliflozin (12 099 [43.1%]) (Figure 1). The gene discussed is SLC5A2; the disease is heart failure.